You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 5,338,732

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,338,732

Title:	Megestrol acetate formulation
Abstract:	The present invention relates to a novel oral pharmaceutical composition of micronized megestrol acetate at a concentration of 15 to 150 mg/mL comprising polysorbate at a concentration of 0.005% to 0.015% weight/volume and polyethylene glycol at a concentration of 5-30% weight/volume which composition forms a stable flocculated suspension in water. The invention further comprises the micronized megestrol acetate formulation described above with added preservatives, buffers, sweeteners and flavoring agents.
Inventor(s):	Atzinger; Anne E. (Lebanon, IN), Bequette; Robert J. (Evansville, IN), Davis; Robert E. (Evansville, IN)
Assignee:	Bristol-Myers Squibb Company (New York, NY)
Application Number:	07/882,218
Patent Claims:	1. An oral pharmaceutical composition comprising micronized megestrol acetate at a concentration of 15 to 150 mg/mL in combination with polysorbate at a concentration of 0.005% to 0.015% weight/volume and polyethylene glycol at a concentration of greater than 5% weight/volume which composition forms a stable flocculated suspension in water. 2. The composition of claim 1 wherein the concentration of micronized megestrol acetate is 20 to 120 mg/mL. 3. The composition of claim 1 wherein the concentration of micronized megestrol acetate is 40 mg/mL. 4. The composition of claim 1 wherein polysorbate 80 is employed. 5. The composition of claim 1 wherein the concentration of polyethylene glycol is from 5% to 30% weight/volume. 6. The composition of claim 1 wherein the concentration of polyethylene glycol is 12 to 24% weight/volume. 7. The composition of claim 1 wherein the concentration of polyethylene glycol is 20% weight/volume. 8. The composition of claim 1 wherein the concentration of polysorbate is 0.01% weight/volume. 9. The composition of claim 1 with buffering, sweetening and flavoring agents. 10. An oral pharmaceutical composition comprising on a percent weight/volume basis megestrol acetate 4%, polyethylene glycol 1450 20%, polysorbate 80 0.01% xanthan gum 0.2%, sodium benzoate 0.2% citric acid 0.244%, sodium citrate 0.015%, sucrose 5%, lemon-lime flavor 0.091%, and the remainder purified water which composition forms a stable flocculated suspension in water.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.